Evidence map›Paper›PMID 28975565›Full record

ArticleMolecular neurobiology2018

Inhibition of β-ARK1 Ameliorates Morphine-induced Tolerance and Hyperalgesia Via Modulating the Activity of Spinal NMDA Receptors.

Xue Zhang, Shaorui Chen, Hong Chen, Huilin Pan, Yilin Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xue ZhangDepartment of Anesthesiology (XZ, YZ), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.
Shaorui ChenCenter for Pain and Neuroscience Research (SC, HC, HP, YZ), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Hong ChenCenter for Pain and Neuroscience Research (SC, HC, HP, YZ), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Huilin PanCenter for Pain and Neuroscience Research (SC, HC, HP, YZ), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yilin ZhaoDepartment of Anesthesiology (XZ, YZ), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China. yilinzhao@hust.edu.cn.ORCID http://orcid.org/0000-0003-2587-0400
The University of Texas MD Anderson Cancer Center · USTongji Hospital · CN

Funding

National Natural Science Foundation of China NO. 81500982
6 · The paper itself

Abstract

Our previous study has proposed that increased presynaptic NMDARs activities play pivotal roles in the development of opioid tolerance and hyperalgesia, and blocking spinal NMDARs attenuates chronic morphine-induced synaptic plasticity and behavior. However, the cellular signaling mechanisms remain to be investigated. The aim of this research was to address the role of β-ARK1 in opioid analgesia. Opioid tolerance and hyperalgesia was induced by daily systemic morphine injections in rats for eight consecutive days. Whole-cell voltage-clamp was employed to record spontaneous EPSCs and evoked-AMPA-EPSCs in dorsal lamina II neurons. Strikingly, brief application of 1 μM morphine decreased the percentage of inhibition and was followed by a large LTP in the amplitude of monosynaptic evoked-AMPA-EPSCs in opioid-tolerant rats. There was no effect on these responses by postsynaptic dialysis of the G-protein inhibitor. Incubation with the NMDAR blocker AP5 potentiated morphine-induced inhibition and attenuated washout potentiation after cessation of morphine in the amplitude of AMPA-EPSCs. Incubation with β-ARK1 inhibitor had the same effect on these responses. Incubation with β-ARK1 inhibitor diminished NMDAR hyperfunction-increased glutamatergic synaptic transmission and enhanced the analgesic effect of morphine. Intrathecal injections of β-ARK1 inhibitor significantly attenuated opioid-induced hyperalgesia and tolerance. β-ARK1 plays a pivotal role in the development and maintenance of opioid tolerance and hyperalgesia. Blockade of β-ARK1 activation ameliorates morphine tolerance and hyperalgesia via regulating the activity of spinal NMDARs. These findings provide electrophysiological evidence and useful insights regarding the mechanistic action of β-ARK1 inhibitor as a potential anti-hyperalgesic agent to improve the efficacy of opioid therapies.

Indexed as

AnimalsGlutamatesG-Protein-Coupled Receptor Kinase 2HyperalgesiaMaleMorphinePresynaptic TerminalsRats, Sprague-DawleyReceptors, N-Methyl-D-AspartateSpinal CordGlutamatesG-Protein-Coupled Receptor Kinase 2MorphineReceptors, N-Methyl-D-AspartateBeta-ARK1Morphine hyperalgesiaMorphine toleranceNMDA receptor

Identifiers

PMID28975565
OpenAlexW2762315620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.